Skip to content
Kalpvruksh Markets
Offline Log in

GLANDNSEOffline

GLAND PHARMA · INE068V01023 · Small Cap · #266
3,145.20−13.80 (−0.44%)last close · 05 Nov 2026
Prev close
3,159.00
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹31,091 cr
52-week range · to 05 Nov 20261,596.83,159

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

GLAND is at its 52-week high, above its 200-day average, ahead of Healthcare by 22.4 pts over 3 months — a Small Cap company, #266 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

F&O · next review 2026-11-16 · our estimateWill GLAND get futures & options?
Strong candidate GLAND has met every criterion we can compute at 3 of the last 3 monthly reviews. NSE also applies an order-size test that is not public, and SEBI approves a few stocks a month.Rank (cap · value): #223 · #173 · Delivery / day: ₹78 crOur estimate, not the exchange’s or the index provider’s. Not advice.

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 50 / 200-day averages · at its 52-week high
  • ahead of its industry by 22.4 pts over 3 months · rank 6 of 44 in Healthcare · +26.3% vs Nifty 500
  • traded value 1.1× usual · delivery 64% vs 54% usual
  • FPI +1.6 pp · DII +2.8 pp · MF schemes in Sept 2026: 60 bought, 55 cut · no promoter pledge · quarter ended 2026-09-30
  • Jun 2026 quarter: profit +47% year on year · revenue +20%
  • ftse large_mid: add candidate (2027-03)

How big is it?

six-month average market cap

Market capitalisation
₹31,091 cr
Rank
#266
Cap band
Small Cap
Nearest cut-off — Mid / Small
−9.07% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
1.3×
median 2,63,016
Delivered
3,46,653
Of volume
72%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+2.3%−3.4 pts—
1 month+4.6%+0.0 pts+0.7 pts
3 months+23.6%+26.3 pts+22.4 pts
6 months+73.6%+72.9 pts+56.6 pts
1 year+65.0%+69.4 pts—

Industry: Healthcare (Nifty 500 classification) · rank 6 of 44 over 3 months. Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+3.7%
above
vs 50-day average
+6.0%
above
vs 200-day average
+36.6%
above
ATR (14)
3.7%
typical daily range
Volatility
34%
1 month, annualised
Beta
0.63
vs Nifty 500, 1 year
Traded value
1.1×
vs usual
Delivery
64%
usual 54%
From the 52-week high
−0.4%
place in range 99% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters51.8%51.8%51.8% −0.145.8% −6.0
FPI7.6%7.3% −0.38.7% +1.510.4% +1.6
Mutual funds31.4%31.8% +0.428.2% −3.629.5% +1.3
Other DII1.6%1.6%2.2% +0.63.7% +1.5
Individuals2.6%2.5%3.5% +1.04.6% +1.1
Others5.0%5.0%5.5% +0.66.0% +0.5

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Jun 25 noneSep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
1,25,667
Individuals
1,17,995

Indian passive funds’ stake

2026-06-30

Of free float
1.15%
Of all shares
0.56%
Schemes
60
Days to unwind
1.9
at 100% of volume

9,17,434 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
139
60 index · 79 active
Bought more
57
Sold some
33
FundSharesChangeDid
WOC Mid Cap Fund-Reg(G)Active+2,11,998+1120.2%bought
DSP Multi Asset Allocation Fund-Reg(G)Active+1,20,262+274.3%bought
HSBC Large & Mid Cap Fund-Reg(G)Active+1,25,382+129.9%bought
Baroda BNP Paribas Health and Wellness Fund-Reg(G)Active−65,000−72.2%sold
ICICI Pru Conservative Hybrid Fund-Reg(G)Active−64,437−64.7%sold
Aditya Birla SL Large & Mid Cap Fund-Reg(IDCW)Active−2,36,013−62.3%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 261562733487+6.3%₹12,935 cr
Aug 2613618601713−4.7%₹12,110 cr
Jul 261311242299−4.8%₹11,021 cr
Jun 261281442308−6.8%₹11,536 cr
May 261221232324−4.7%₹11,159 cr
Apr 26114148163−0.1%₹9,111 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
No market buy or sell
Others
No market buy or sell
Latest 2 of 69 disclosures
0 selected
20 Jun 2024FOSUN PHARMA INDUSTRIAL PTE. LTDPromotersSell99,00,000₹1,754 cr51.83%Market Sale
15 Mar 2024K.V.G.K.RAJUKey Managerial PersonnelSell7,992₹1.43 cr0.00%Market Sale

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Scheme / acquisition
    Acquisition (including agreement to acquire)-XBRL GLAND PHARMA LIMITED has informed the Exchange regarding Acquisition (including agreement to acquire)
    05 Oct 2026
  • Board outcome
    Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2026.
    01 Oct 2026
  • Board outcome
    Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 13, 2026.
    15 Sept 2026
  • Scheme / acquisition
    Acquisition (including agreement to acquire)-XBRL GLAND PHARMA LIMITED has informed the Exchange regarding Acquisition (including agreement to acquire)
    15 Sept 2026
  • Board outcome
    Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    10 Aug 2026
  • Board outcome
    Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 15, 2026.
    16 Jun 2026
  • Block deal: BUY
    1,50,000 at ₹2,826.6 — BOFA SECURITIES EUROPE SA
    17 Sept 2026
  • Block deal: SELL
    1,50,000 at ₹2,826.6 — NORTH ROCK SG VCC
    17 Sept 2026

GLAND: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
EarlierDividend₹20Final11 Aug 202611 Aug 2026
EarlierDividend₹18Final14 Aug 202514 Aug 2025
EarlierDividend₹20Final16 Aug 202416 Aug 2024

3 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.